Piramal Pharma Limited Announces Results for Q2 and H1 FY27

What happened

Piramal Pharma reported Q2 FY27 revenue from operations of 2,617 crore rupees, up 28% year on year, and H1 revenue of 4,887 crore rupees, up 23%, with EBITDA rising 72% in both periods.

Confirmed

Global impact / market context

Faster revenue across all three businesses plus 72% EBITDA growth means more profit per sale, helped by higher use of factory capacity and cost cuts, which can fund future growth and improve returns for investors.

Analyst inference

The results show broad demand for Piramal's contract manufacturing and health businesses, with 22 new customers added. Stronger margins and profit reduce pressure on cash needs and may support the company's spending plans.

Analyst inference

What to watch

1. Piramal completed 12 regulatory inspections and 110 customer audits in H1FY27, maintaining a record of no official observations, which supports its ability to win and keep contracts. Confirmed
2. Watch whether Piramal converts its strong request-for-proposal activity and 22 new customers into signed orders and revenue in coming quarters, since these are early signs rather than booked sales. Proposed
3. Watch whether higher factory utilization and cost savings keep EBITDA margin near 14.7%, because a drop would lower profit per sale and could reduce cash available for growth spending. Analyst inference

Evidence

• Original source link unavailable